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Abstract
Background: Europeans represent the majority of international travellers and clinicians encountering returned
patients have an essential role in recognizing, and communicating travel-associated public health risks.
Methods: To investigate the morbidity of travel associated infectious diseases in European travellers, we analysed
diagnoses with demographic, clinical and travel-related predictors of disease, in 6957 ill returned travellers who
presented in 2008 to EuroTravNet centres with a presumed travel associated condition.
Results: Gastro-intestinal (GI) diseases accounted for 33% of illnesses, followed by febrile systemic illnesses (20%),
dermatological conditions (12%) and respiratory illnesses (8%). There were 3 deaths recorded; a sepsis caused by
Escherichia coli pyelonephritis, a dengue shock syndrome and a Plasmodium falciparum malaria.
GI conditions included bacterial acute diarrhea (6.9%), as well as giardiasis and amebasis (2.3%). Among febrile sys-
temic illnesses with identified pathogens, malaria (5.4%) accounted for most cases followed by dengue (1.9%) and
others including chikungunya, rickettsial diseases, leptospirosis, brucellosis, Epstein Barr virus infections, tick-borne
encephalitis (TBE) and viral hepatitis. Dermatological conditions were dominated by bacterial infections, arthropod
bites, cutaneous larva migrans and animal bites requiring rabies post-exposure prophylaxis and also leishmaniasis,
myasis, tungiasis and one case of leprosy. Respiratory illness included 112 cases of tuberculosis including cases of
multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of
Legionnaires disease. Sexually transmitted infections (STI) accounted for 0.6% of total diagnoses and included HIV
infection and syphilis. A total of 165 cases of potentially vaccine preventable diseases were reported. Purpose of
travel and destination specific risk factors was identified for several diagnoses such as Chagas disease in immigrant
travellers from South America and P. falciparum malaria in immigrants from sub-Saharan Africa. Travel within Eur-
ope was also associated with health risks with distinctive profiles for Eastern and Western Europe.
Conclusions: In 2008, a broad spectrum of travel associated diseases were diagnosed at EuroTravNet core sites.
Diagnoses varied according to regions visited by ill travellers. The spectrum of travel associated morbidity also
shows that there is a need to dispel the misconception that travel, close to home, in Europe, is without significant
health risk.
Background
In 2008, Europeans continued to represent the majority
of international travellers (n = 508.7 million, 55.2%) and
Europe remained the world’s largest destination region
(n = 489.4 million, 53%) despite suffering an overall
stagnation in arrivals as compared to 2007 (+0.3%) [1].
Tourism, international business travel, immigration and
travel for international aid work make up important
components in the travel market. Such intense interna-
tional traffic between Europe and the rest of the world,
along with significant intra-European migration, results
in greater vulnerability to the transmission of old, new
and re-emerging infectious diseases, with travellers as a
key element in disease dissemination [2].
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Numerous outbreaks and case reports serve as remin-
ders that infections can be imported and/or transmitted
in Europe by visiting or returning travellers. This was
illustrated by severe acute respiratory syndrome (SARS)
in 2003 [3], chikungunya virus (CHIKV) in Italy 2007
[4] and most recently by the rapid spread of influenza A
(H1N1) in 2009 [5]. Recognising and tracking such
health threats clearly requires accurate surveillance and
active collaboration allows European surveillance net-
works to successfully follow regional trends and detect
international outbreaks of concern and provide accurate
data on which evidence-based travel health policies and
recommendations can be made.
EuroTravNet http://www.eurotravnet.eu, a network of
clinical specialists in tropical and travel medicine was
founded in 2008, to assist the European Centre for Dis-
ease Prevention & Control (ECDC) for the detection,
verification, assessment and communication of commu-
nicable diseases that can be associated with travelling
and specifically with tropical diseases [2]. EuroTravNet
core sites also participate in surveillance and monitoring
of travel-related illnesses by collecting epidemiologic
data, linking diagnoses with exposure information, of
returned ill travellers. Data collected using a standar-
dised format, are entered into the international Geosen-
tinel http://www.geosentinel.org database and analysed
periodically [6]. This report describes the spectrum of
infectious diseases in European travellers during 2008,
grouped by specified clinical syndrome categories with
focused sub-analyses of specific conditions, and emer-
ging diseases.
Methods
Travellers who presented from 1st January - 31st Decem-
ber 2008 to a EuroTravNet core site (Figure 1) during
or after travel were included. Data that could not be
linked back to an individual patient were collected
according to a standardised, anonymised questionnaire
and entered by all EuroTravNet core sites into a data-
base [7]. Reasons for travel were classified as: tourism,
business, missionary/volunteer/research/aid work
(MVRAs), student, military, health-care seeking, or visit-
ing friends and relatives (VFRs) [7]. Individual countries
visited were grouped into 12 regions; see figure 1. Medi-
cal data included the final diagnosis as assigned by the
treating clinician, using his own diagnosis procedure
and facilities, according to a standardised list of 556
possible individual diagnoses that were also categorized
under 21 broad syndromes as previously described [7].
Patients were assigned as many diagnosis codes as
needed. Specific diagnoses were also highlighted.
Exposure Country is the country specified by the con-
sulted physician as the country where exposure most
likely happened. A sub-analysis compared travellers who
were likely exposed in Europe to those who were likely
exposed outside of Europe. “All other travellers”
includes those who were known to be exposed outside
of Europe, those where no country/region was ascertain-
able by the physician, those who had possible exposure
in more than 1 country and where the exposure coun-
tries were in different regions, or the diagnoses could
not be attributed to a single travel exposure (e.g. fatigue,
anaemia of an unknown aetiology). We defined Wait
Time as the shortest time in days from the end of the
last travel trip to the date of initial clinic visit, regardless
of which trip resulted in potential exposure. We esti-
mated the total length of time spent travelling using the
sum of the durations of all the travel that had ended in
the last 6 months duration, + 30 days for each trip from
more than 6 months ago where they stayed at least 30
days (“Duration Sum”).
Data were analyzed in SPSS v16.0®. In our evaluation,
proportionate morbidity compares the number of cases
of a specific diagnosis (or of a group of specific diagnosis
within a syndrome group) to all cases of ill returned tra-
vellers seen during the same time period [6]. Differences
in proportions between sub-groups ("Exposed in Europe”
and “All other travellers”) of ill returned travellers seen at
EuroTravNet cores sites were tested using Pearson Chi-
square or Fisher exact tests. Kruskal-Wallis and Mann-
Whitney tests were used for quantitative variables. A sig-
nificant p-value < 0.01 was chosen to adjust for the large
number of statistical tests performed.
Ethics approval
The GeoSentinel International data-collection protocol
used by EuroTravNet was reviewed by the institutional
review board officer at the National Center for Infec-
tious Diseases at the Centers for Disease Control and
Prevention and classified as public health surveillance
Figure 1 Demographic and travel data of 6957 ill returned
travellers seen in EuroTravNet core sites in 2008.
Field et al. BMC Infectious Diseases 2010, 10:330
http://www.biomedcentral.com/1471-2334/10/330
Page 2 of 12
and not as human-subjects research requiring submis-
sion to institutional review boards. However, where
required by local regulations, the institutional review
boards of each European Institutions belonging to Geo-
sentinel/EuroTravNet reviewed and approved the Geo-
Sentinel data-collection protocol and its use for data
analyses.
Results
In 2008, EuroTravNet core sites captured data from a
broad range of travellers, as shown in Figure 1. Data of
6957 ill travellers were analysed. Demographic and travel
data are respectively presented in Table 1 and Figure 2.
Spectrum of diseases
Gastro-intestinal diseases accounted for 33% of illnesses,
followed by febrile systemic illnesses (20%), dermatologi-
cal conditions (12%) and respiratory illnesses (8%). The
related morbidity of broad syndromes and selected diag-
noses according to region of travel was presented in
Table 2. There were three deaths in the dataset. The
first case was that of a 53 year old Norwegian who died
from Dengue Shock Syndrome following a three week
pre-arranged tourist trip to Phuket, Thailand. The sec-
ond case is that of a 57-year old aid worker who visited
Liberia for three weeks. He was admitted with coma as
a result of severe malaria, a week after return to Geneva,
and subsequently acquired a nosocomial infection and
died of septic shock. The third case was a 67 year old
Norwegian who died from E.coli pyelonephritis and sep-
sis, following a two month visit to Spain; details of
underlying pathology are not known.
Etiologic diagnosis
The related morbidity of selected diagnoses according to
region of travel is presented in Table 3. Acute diarrhea
was the most frequent gastro-intestinal concern and
acquired from all traveled regions although there are
regional differences. Among identified pathogens, Shi-
gella spp accounted for most cases. There were 284
pathogenic intestinal protozoan infections reported
including 193 Giardia intestinalis (the second most
common identified pathogen responsible of acute diar-
rhea), 16 cases of cryptosporidiosis, mostly from Egypt
and India, and 12 cases of cyclosporiasis (worldwide dis-
tribution). Within 156 cases of helminthic infections, 54
cases of strongyloidiasis and 10 cases of loiasis were
reported. Nine cases of hepatitis E were diagnosed
including 4 cases from Pakistan, 2 from India, 2 from
Bangladesh, and 1 from Sudan. A total of 129 cases of
schistosomiasis were reported, the majority acquired by
MVRAs (48.8%; n = 63), tourists (19.4%; n = 25) and
VFRs (14.0%; n = 18), in sub-Saharan Africa (SSA)
(61.2%; n = 79), namely Uganda (n = 15), Tanzania (n =
8), Malawi and Ghana (n = 7) and North Africa (10.1%;
n = 13), namely Egypt (n = 8) and Sudan (n = 5). The
majority of schistosomiasis cases (n = 113) did not have
species specific diagnoses; there were 8 cases of Schisto-
soma mansoni (mostly from SSA), and 8 cases of S. hae-
matobium (mostly from SSA).
Among febrile systemic illnesses with an identified
pathogen, malaria accounted for most cases followed by
dengue. A total of 371 cases of uncomplicated malaria
were reported including 255 Plasmodium falciparum
infections; an additional 5 cases were reported as severe
complicated cerebral malaria and 7 cases as severe,
complicated non-cerebral malaria. One of these cases
proved fatal. The majority of P. falciparum (87.1%) was
acquired in SSA, namely Comoros Islands, Ghana, Ivory
Coast, Cameroon and Nigeria, and by VFRs (65.9%).
Also, 31 cases of P. vivax (mostly from South Central
Asia (India, Pakistan, Afghanistan), South America
Table 1 Proportion of different categories of travellers
among 6957 patients seen at EuroTravNet core sites in
2008
Patients 6957
Male 3556 (51.1%)
Female 3398 (48.9%)
Median age (min;max) 36 (0-89)
Inpatient 769 (11.1)
Outpatient 6188 (90%)
Born in Europe 5286 (76%)
Born Outside Europe 1671 (24%)
Residence in Europe 6358 (91.4%)
Residence Outside Europe 599 (8.6%)
Travel reason
Tourism 3029 (43.5%)
MVRA 1569 (22.6)
VFRs 831 (11.9%)
Business 731 (10.5%)
Immigration 655 (9.4%)
Student 91 (1.3%)
Military 40 (0.6%)
Medical Tourism 10 (0.1%)
Unknown 1 (0.0%)
Pre-travel advice
Yes 3160 (45.4%)
No 1554 (22.3%)
Unknown 2243 (32.2%)
Median Duration Sum
(min-max) (days)
29 (0-14600)
Median Wait time (min-max) (days) 16 (0-13625)
This proportion includes 41 from Amsterdam, The Netherlands, 136 from
Brescia, Italy, 126 from Cambridge, UK, , 417 from Geneva, Switzerland, 1480
from Hamburg, Germany, 1132 from London, UK, 456 from Madrid, Spain, 351
from Marseille, France, 1547 from Munich, Germany, 498 from Oslo, Norway,
548 from Paris, France, and 225 from Zurich, Switzerland. VFRs: Visiting
Friends and relatives. MVRAs: missionary, volunteer, research, or aid work.
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(French Guiana and Brazil), and SSA), 25 cases of P.
ovale (mostly SSA (Ivory Coast, Comoros, Guinea)) and
14 cases of P. malariae (all from SSA) were diagnosed.
The countries of acquisition of malaria in our returned
travellers are shown in Figure 3.
Dengue was diagnosed in 131 patients with 1 death.
The majority (45.8%) of dengue cases were acquired in
South East Asia, notably Thailand (n = 32), Indonesia (n
= 7), Myanmar (n = 4) and Vietnam (n = 6). 16.0% was
acquired in South Central Asia, notably India (n = 14),
Maldives (n = 4) and Sri Lanka (n = 2); 9.9% were
acquired in South America, notably Brazil (n = 7); 6.9%
of cases were acquired in SSA (Burkina Faso, Cameroon,
Cote D’Ivoire, Gabon, Mali and Senegal). The majority
were diagnosed in tourists (61.1%) and imported into
Germany (58.8%) and France (17.6%).
A total of 12 cases of chikungunya virus (CHIKV)
were acquired in Indian Ocean Islands of Reunion (n =
3), Comoros (n = 2), Sri Lanka (n = 2), Madagascar (n =
1), Maldives (n = 1), as well as from India (n = 1). Cases
were also imported from Kenya (n = 1) and Senegal (n
= 1). The majority were diagnosed in tourists and
imported into France and Germany.
Among 50 cases of reported rickettsial diseases (74%
in tourists), spotted fever group rickettsioses accounted
for the majority of cases (86.0%); most of these were
African tick bite fever acquired in South Africa (n = 28),
Tanzania, Mozambique, Uganda, Namibia, Kenya, Ethio-
pia and Gambia. Mediterranean spotted fever was diag-
nosed in 4 cases, acquired in France (n = 2), Greece (n
= 1) and Spain (n = 1). One case of scrub typhus was
reported from India.
Other febrile illnesses included 7 cases of leptospirosis
that were acquired in Cambodia (n = 2), Cameroon (n =
1), Central African Republic (n = 1), Costa Rica (n = 1),
Indonesia (n = 1) and Reunion (n = 1), by tourists (n =
4) and business travellers (n = 3); two cases of acute
brucellosis, respectively in a tourist following a trip to
Thailand and in a VFR who was exposed on a return
visit to his country of birth Algeria; three cases of toxo-
plasmosis, 20 cases of acute Epstein Barr Virus infection,
and one case of histoplasmosis.
Bacterial infections accounted for most dermatological
diagnoses followed by arthropod bites and cutaneous
larva migrans (Table 2). Also, 80 animal bites (including
dog, cat and monkey bites) were reported including 65
(81.3%) known to have been treated with rabies post-
exposure prophylaxis (PEP). The majority of exposures
occurred in Thailand (16.3%; n = 13), Algeria (13.8%; n
= 11) and Morocco (8.8%; n = 7) and were seen in tour-
ists (68.8%) and VFRs (22.5%).
A total of 15 cases of leishmaniasis, 12 cutaneous, 1
mucocutaneous, and 2 visceral, were reported. Cases of
cutaneous leishmaniasis were acquired in North Africa
(Morocco n = 2, Sudan n = 2), Central and South
America (Costa Rica n = 1, Ecuador n = 1, Guatemala n
= 1, Peru n = 1), South Central Asia (Afghanistan n =
1), and Western Europe (Malta n = 1); two exposures
were unascertainable. The case of mucocutaneous leish-
maniasis was acquired in Venezuela. One case of visc-
eral leishmaniasis was acquired in Spain. The majority
of cases, 66.7%, were acquired by tourists (n = 10) and
imported into Germany (n = 9). Other dermatological
diagnosis reported included 22 cases of myiasis, 13 cases
Figure 2 Regions (according to GeoSentinel classification7) visited by 6957 ill returned travellers seen in EuroTravNet core sites in
2008.
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of tungiasis, and one case of leprosy in a 24 year old
Somalian-born immigrant to Switzerland.
Respiratory illnesses that were reported included 104
Influenza-like illnesses (ILIs), and 8 cases of influenza A
and 2 cases of influenza B. Of the 68 cases with a
reported country of exposure, the majority (n = 43)
were exposed in SSA. There were 112 cases of Mycobac-
terium tuberculosis (TB) infections including 64 in
immigrants, 32 in VFRs (mostly foreign-born), 6 tour-
ists, 1 student, 1 MVRAs and 8 business travellers.
There were 39 cases of pulmonary TB, 6 cases were of
MDR or XDR TB, 5 of TB meningitis, 4 of CNS
Table 2 Selected syndrome groups according to travel region among 6957 patients seen at EuroTravNet core sites in
2008
Total
N %
Caribbean Central
America
Europe Middle
East
North
Africa
North
East
Asia
Other South
America
South
Central
Asia
South
East
Asia
Sub-
Saharan
Africa
No
single
region
Febrile/Systemic
Illness
1378 23 21 46 16 22 17 9 70 116 160 602 276
20% 20% 16% 14% 15% 7% 22% 12% 15% 17% 25% 33% 13%
Acute Diarrhea 1205 27 42 67 33 119 15 6 70 263 131 319 113
17% 24% 32% 20% 31% 36% 19% 8% 15% 39% 21% 18% 5%
Chronic
Diarrhea
484 9 14 11 10 53 5 4 41 71 57 85 124
7% 8% 11% 3% 9% 16% 6% 6% 9% 11% 9% 5% 6%
Gastrointestinal
Other
623 8 16 30 12 29 11 6 44 70 44 176 177
9% 7% 12% 9% 11% 9% 14% 8% 9% 10% 7% 10% 8%
Dermatologic 851 35 34 62 14 43 9 27 83 72 140 216 116
12% 30% 26% 18% 13% 13% 12% 37% 18% 11% 22% 12% 5%
Respiratory 540 8 6 72 10 15 4 8 18 65 65 119 150
8% 7% 5% 21% 9% 5% 5% 11% 4% 10% 10% 7% 7%
Tissue Parasites 237 0 0 5 2 10 0 1 96 2 3 85 33
3% 0% 0% 2% 2% 3% 0% 1% 20% 0% 1% 5% 2%
GU and STIs 200 6 2 16 2 7 1 0 11 17 23 44 71
3% 5% 2% 5% 2% 2% 1% 0% 2% 3% 4% 2% 3%
Psychologic 175 2 0 6 3 14 5 0 7 18 5 52 63
3% 2% 0% 2% 3% 4% 6% 0% 2% 3% 1% 3% 3%
Injury/
Musculoskeletal
144 2 1 16 3 9 9 5 10 13 13 24 39
2% 2% 1% 5% 3% 3% 12% 7% 2% 2% 2% 1% 2%
Neurologic 98 1 0 13 3 7 1 3 3 8 8 22 29
1% 1% 0% 4% 3% 2% 1% 4% 1% 1% 1% 1% 1%
Death 3 0 0 1 0 0 0 0 0 0 1 1 0
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Chronic Disease 319 1 1 17 1 4 4 2 61 9 13 107 99
5% 1% 1% 5% 1% 1% 5% 3% 13% 1% 2% 6% 5%
Nonspecific
Symptoms
283 4 6 8 2 13 3 3 38 14 19 91 82
4% 4% 5% 2% 2% 4% 4% 4% 8% 2% 3% 5% 4%
Other 347 6 11 18 6 17 5 7 27 24 42 107 77
5% 5% 8% 5% 6% 5% 6% 9% 6% 4% 7% 6% 4%
Healthy 1056 1 3 3 5 5 1 0 8 9 4 36 981
15% 1% 2% 1% 5% 2% 1% 0% 2% 1% 1% 2% 45%
Total 6957 115 133 341 107 330 78 73 470 676 631 1804 2199
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
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Table 3 Selected etiologic diagnoses according to travel region among 6957 patients seen at EuroTravNet core sites in
2008
Total
N %
Caribbean Central
America
Europe Middle
East
North
Africa
North
East
Asia
Other South
America
South
Central
Asia
South
East
Asia
Sub-
Saharan
Africa
No
single
region
Acute Diarrhea 1205 27 42 67 33 119 15 6 70 263 131 319 113
17% 24% 32% 20% 31% 36% 19% 8% 15% 39% 21% 18% 5%
Campylobacter 87 0 0 4 6 6 2 0 4 25 17 16 7
1% 0% 0% 1% 6% 2% 3% 0% 1% 4% 3% 1% 0%
Shigella 333 5 8 13 11 27 4 1 12 76 31 108 37
5% 4% 6% 4% 10% 8% 5% 1% 3% 11% 5% 6% 2%
Salmonella NT 59 1 1 5 1 7 1 0 3 5 7 19 9
1% 1% 1% 2% 1% 2% 1% 0% 1% 1% 1% 1% 0%
Giardia 193 2 5 7 4 7 0 0 13 74 15 47 19
3% 2% 4% 2% 4% 2% 0% 0% 3% 11% 2% 3% 1%
Amebas 25 1 1 0 0 1 0 0 2 10 1 7 2
0% 1% 1% 0% 0% 0% 0% 0% 0% 2% 0% 0% 0%
Febrile 1378 23 21 46 16 22 17 9 70 116 160 602 276
Systemic* 20% 20% 16% 14% 15% 7% 22% 12% 15% 17% 25% 33% 13%
P. falciparum
Malaria
255 2 0 0 0 2 0 0 1 3 0 241 6
4% 2% 0% 0% 0% 1% 0% 0% 0% 0% 0% 13% 0%
Malaria other 116 0 0 0 0 2 0 3 11 12 1 82 5
2% 0% 0% 0% 0% 1% 0% 4% 2% 2% 0% 5% 0%
Dengue 131 6 7 0 0 1 1 0 13 21 60 9 13
2% 5% 5% 0% 0% 0% 1% 0% 3% 3% 10% 1% 1%
Chikungunya 12 0 0 0 0 0 0 0 0 4 0 8 0
0% 0% 0% 0% 0% 0% 0% 0% 0% 1% 0% 0% 0%
Rickettsiosis 50 0 0 6 1 0 2 0 1 1 0 36 3
1% 0% 0% 2% 1% 0% 3% 0% 0% 0% 0% 2% 0%
Salmonellosis 20 0 0 1 0 1 0 0 0 8 2 6 2
0% 0% 0% 0% 0% 0% 0% 0% 0% 1% 0% 0% 0%
Dermatologic 851 35 34 62 14 43 9 27 83 72 140 216 116
12% 30% 26% 18% 13% 13% 12% 37% 18% 11% 22% 12% 5%
Rabies PEP 65 0 2 6 4 19 1 2 5 2 17 7 0
1% 0% 2% 2% 4% 6% 1% 3% 1% 0% 3% 0% 0%
Arthropods’ bite 177 9 5 24 3 5 2 7 18 14 43 37 10
3% 8% 4% 7% 3% 2% 3% 10% 4% 2% 7% 2% 1%
Larva migrans 97 3 6 1 0 1 0 2 17 10 24 28 5
1% 3% 5% 0% 0% 0% 0% 3% 4% 2% 4% 2% 0%
Bacterial
infection
229 14 11 15 5 6 2 9 13 23 33 63 35
3% 12% 8% 4% 5% 2% 3% 12% 3% 3% 5% 4% 2%
Leishmaniasis 15 0 2 1 0 3 0 0 3 1 0 0 5
0% 0% 2% 0% 0% 1% 0% 0% 1% 0% 0% 0% 0%
Myiasis 22 0 3 0 0 0 0 0 6 0 0 12 1
0% 0% 2% 0% 0% 0% 0% 0% 1% 0% 0% 1% 0%
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tuberculoma, 19 of disseminated/miliary TB, and 39
other cases reported as extrapulmonary TB. Also, 5
cases of Legionnaire’s disease were mostly in tourists,
including 2 with known exposures in Spain.
Chagas disease (Trypanosoma cruzi) was diagnosed in
94 patients. The majority were exposed in Bolivia
(95.7%; n = 90), and imported into Spain (97.9%; n =
92) by immigrant travellers (98.9%; n = 93). Two cases
were imported from Ecuador, 1 from Argentina and 1
from Paraguay. Most cases (95.7%; n = 90) were con-
firmed when screening patients with no specific com-
plaints of Chagas disease. Two cases presented with
musculoskeletal pain and two with gastrointestinal
symptoms.
The proportionate morbidity of genito-urinary and
sexual transmitted infections (STIs) was 2.9%. A total of
52 newly-diagnosed asymptomatic HIV cases were
reported, mostly in immigrants (n = 32) but also 10 in
tourists, 6 in VFRs, 3 in students, and 1 in a business
traveller. There was a further 43 cases of asymptomatic
HIV, and 32 cases of AIDS, reported mostly in immi-
grants and VFRs. Place of exposure was difficult to
ascertain. Also, 21 cases of syphilis were reported, the
majority in male (n = 16), immigrant or foreign-born
VFR travellers (n = 14).
Finally, there were 166 cases of potentially vaccine
preventable diseases reported including 23 cases of
acute hepatitis A, 9 cases of acute hepatitis B, 2 cases of
measles, 4 cases of Haemophilus influenzae B meningi-
tis, 1 case of pneumococcal meningitis, 3 cases of per-
tussis, 1 case of tick borne encephalitis (from Estonia), 9
cases of typhoid fever, 4 cases of acute varicella, and the
cases of influenza A (8 patients) and influenza B (2
patients) presented above. The majority of these ill-
nesses were acquired by tourists and business travellers.
Immigrants and VFRs travellers accounted for the
majority of cases of chronic hepatitis B carriage (n =
99), diphtheria (n = 2) and TBE (n = 1). The cases of
diphtheria were those of a 5 year old boy, born and
raised in Norway, who travelled with his mother to her
homeland to visit friends and relatives in Latvia. The
boy presented with fever and ear, nose and throat symp-
toms, one week after their return and was diagnosed
with diphtheria. His mother was positive on asympto-
matic screening.
European travel sub-set
When comparing travellers who were likely exposed in
Europe to those who were likely exposed outside of Eur-
ope, significant differences (p < 0.01) were found in
Figure 3 Countries of acquisition of malaria in ill returned travellers to EuroTravNet core sites in 2008.
Table 3: Selected etiologic diagnoses according to travel region among 6957 patients seen at EuroTravNet core sites
in 2008 (Continued)
Respiratory 540 8 6 72 10 15 4 8 18 65 65 119 150
8% 7% 5% 21% 9% 5% 5% 11% 4% 10% 10% 7% 7%
STIs 42 0 0 4 0 1 0 0 3 1 6 10 17
1% 0% 0% 1% 0% 0% 0% 0% 1% 0% 1% 1% 1%
Schistosomiasis 129 0 0 2 1 11 0 0 2 2 2 79 30
2% 0% 0% 1% 1% 3% 0% 0% 0% 0% 0% 4% 1%
Cases of dengue reported by EuroTravNet core sites in Brescia, Italy and Oslo, Sweden have been included in [34]
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relation to several variables. Those exposed in Europe
were more likely to have been born in Europe, currently
live in Europe, be younger, not seek pre-travel advice,
travel for shorter trips, be VFRs or tourists, be more
likely to require inpatient care, and were less likely to be
business travellers, or MVRAs. There were no signifi-
cant differences between those exposed in Europe and
all other travellers in relation to gender, or time to pre-
sentation. These results were not affected by excluding
or including patients who came to a clinic for asympto-
matic screening, usually after missionary volunteer work
and were found to be healthy (n = 953).
In those Europeans who returned from a trip within
Europe, 16.9% had acquired a gastro-intestinal illness
(including acute and chronic unspecified diarrhea, giar-
diasis, Campylobacter infection and non-typhi salmonel-
losis); 14% had acquired a respiratory illness (including
bacterial pneumonia, upper respiratory tract infection,
acute bronchitis and atypical pneumonia); and 7.9% had
a dermatological condition (including insect bite, dog
bite, tick bite, skin abscess and infection).
Of those Europeans who were exposed in Western
Europe (n = 283), the majority were tourists (n = 204),
travelling from where they lived in Norway (n = 37),
Germany (n = 34), or Switzerland (n = 32), and France
(n = 22), to Spain (n = 83), Germany (n = 74) and Italy
(n = 43); 27.2% (n = 77) had sought pre-travel advice.
The most common diagnoses were respiratory illness
(11%), gastro-intestinal illness (10.9%) and insect bites
(5.7%). Of those Europeans who were exposed in East-
ern Europe (n = 145), the majority was VFRs (n = 83),
travelling from where they lived in Switzerland (n = 72)
or Germany (n = 20), to Serbia (n = 29), Russia (n =
20), Albania (n = 18), Macedonia (n = 12) and Croatia
(n = 9).
Gastro-intestinal illness was reported in 22.1% of
patients who travelled to Eastern Europe, compared to
10.9% in those who travelled to Western Europe.
Respiratory illness accounted for 14.5% of diagnoses
from Eastern Europe compared to 11% from Western
Europe. Dog bites resulting in rabies post-exposure
treatment was reported in 9 cases (6%) following travel
to Eastern Europe. Insect bites were reported in 8 cases
following travel to Western Europe.
Additionally, in those who travelled to Western Eur-
ope as compared to Eastern Europe, more cases of
potentially vaccine preventable illness (including influ-
enza A and B, pneumococcal meningitis, Salmonella
typhi and varicella) and acute STIs (including acute
symptomatic and asymptomatic newly diagnosed HIV
and chlamydia) were reported. Four cases of ricketssial
disease, Mediterranean Spotted Fever, were also diag-
nosed. More cases of TB (including MDR or XDR, pul-
monary, disseminated, meningitis, extrapulmonary and
asymptomatic tuberculin PPD positive), acute hepatitis
A and tick bites were reported in those who travelled to
Eastern Europe as compared to Western Europe.
Discussion
EuroTravNet captures a sentinel sample of travellers.
This analysis details the complex epidemiology of travel
associated morbidity in European travellers and high-
lights the different profiles of travel-acquired illness in
different types of travellers. Furthermore, the spectrum
of disease associated with travel within Europe (Eastern
and Western Europe) is evaluated and risk areas and
groups are identified. Each EuroTravnet site has specific
characteristics, and some could be considered as sentinel
sites for diseases in specific categories of travelers
returning from particular countries. However, surveil-
lance in European travelers that encompasses a wide
range of sites in Europe, including some with local spe-
cificity, is crucial to determine the epidemiology of tra-
vel-associated disease, to detect alarming events, and, if
required, to organize a rapid response [6]. The major
strengths of our analysis are its multi-centre nature pro-
viding a large number of participants from twelve Eur-
opean countries, capturing all traveller types, and its
focus on proportionate disease as a risk indicator. The
limitations of this method of risk analysis have been
recently discussed [6]. Particularly, because the denomi-
nator data (numbers of travellers) cannot be ascertained,
it is not possible to calculate incidence rates. However,
despite this limitation, the EuroTravNet/Geosentinel
database analysis has been identified as a main source of
data on the epidemiology of travel-related illness [6-10].
Because of the lack of data collected on injuries and
accidents, which are frequent causes of travel associated
morbidity and mortality, we focused here on infectious
diseases morbidity. We selected and discussed specific
causes among the main syndromes affecting European
travellers, including gastro-intestinal disorders, febrile
systemic illness, dermatological problems and respira-
tory diseases, focusing on emerging diseases or diseases
of importance for public health in Europe.
During the 20th century, malaria was eradicated from
the whole of the European Union (EU). The potential
for the reappearance is a constant concern as potential
vectors remain present. Continued surveillance remains
important to update guidelines for malaria chemopro-
phylaxis, as malaria remains the first common specific
diagnosis in febrile returned travellers. Since 2000, a
slight but steady decrease in the overall incidence rates
of imported malaria in Europe has been observed; how-
ever, all evaluations of imported malaria show an
increasing proportion of life-threatening P. falciparum
malaria in certain risk groups such as those visiting
friends and relatives, as shown here [11,12]. Our data
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show VFRs returning from SSA continue to be those
most at risk of P. falciparum and are those most in
need of targeted pre-travel health advice.
Of note in 2008, cases of P. falciparum malaria,
respectively imported from Bahamas [13], and the
Dominican Republic [14], and reported to ProMed by
the Hamburg site, intensified surveillance by health pro-
fessionals, but also highlighted differences in malaria
chemoprophylaxis recommendations across Europe This
is also the case for India [15] (3 cases reported herein).
An interesting paper by Calleri et al describes the varia-
bility of malaria chemoprophylaxis among “experts” in
Europe [16].
Increased dengue activity was reported throughout
endemic areas of the world during 2008, including
South Central Asia, notably India, and South America,
notably Brazil as compared to 2007 [17]. Several cases
were reported from Asia, including cases in travellers to
Bali, Indonesia, the Philippines, Thailand, Viet Nam and
Myanmar. Five cases were imported into Marseille,
France and one case into Brescia, Italy, close to areas
inhabited by the mosquito vector Aedes albopictus, with
the potential threat of onward transmission in Europe
[18]. Figure 4 shows a map of the countries of acquisi-
tion and countries of importation of dengue cases
reported by EuroTravNet core sites and the overlapping
area of habitation of Ae. albopictus [18].
In addition to mosquito bite prevention for all travel-
lers to endemic areas, it is also essential to stress the
potential risk of dengue for MVRA workers in specific
circumstances, such as those working in Myanmar as
part of the international relief effort in Bogale. This
delta region was flooded by the tidal wave which fol-
lowed Cyclone Nargis in May 2008. After the index case
reported in London [19], three more cases were diag-
nosed in returned travellers from Myanmar by Euro-
TravNet core sites in 2008.
Chikungunya virus (CHIKV) infection emerged in
the field of travel medicine in 2005-2009, since an epi-
demic spread to the islands throughout the Indian
Ocean and to India [20]. More than a thousand cases
of imported CHIKV infection in travellers returning
from La Reunion (French territory) and other Indian
Ocean islands have been reported by France, but also
by many other European countries. Recent cases have
been diagnosed in travellers returned from tourist des-
tinations where outbreaks re-emerged, such as Thai-
land [21]. The justified concern in Europe regarding
the risk of introduction and transmission of CHIKV
was illustrated in 2007 when a single returned traveller
was identified as the cause of an outbreak in August
2007 in Italy [4]. At this time there was evidence for
indigenous transmission via Ae. albopictus mosquitoes
that are very active during the summer in this area,
and have been shown to be efficient vectors in the
transmission of the CHIKV variant responsible for the
recent and ongoing outbreak [20]. The presence of A.
albopictus in areas in Europe makes early detection of
imported cases of CHIKV infection essential to prevent
emergence of this disease. Of note, 5 of the 12 cases of
CHIKV reported here were imported into Marseille,
France, less than 150 km from areas where Ae. albo-
pictus has been detected.
Chagas disease (CD) is endemic in Central and South
America where it affects around 16 to 18 million people.
This parasitic infection caused by Trypanosoma cruzi
has also emerged in the field of travel medicine [22].
Worldwide, Spain is second to the US in having the lar-
gest number of immigrants from Latin America. In
2008, a total of 1,607,699 were from T. cruzi endemic
areas; of these, 239,942 are from Bolivia, the country
with the highest prevalence of T. cruzi infection. Up to
10% of Bolivian blood donors in Spain had antibodies to
T. cruzi [23]. This is also illustrated by the majority of
cases of CD reported by EuroTravNet in 2008 that were
imported from Bolivia to Spain. Given that the infection
can be transmitted in non-endemic countries congeni-
tally, by organ donations and blood transfusions, Chagas
disease could be regarded as an emerging public health
problem in Europe and centres seeing immigrants from
Figure 4 Countries of acquisition and countries of importation of dengue and chikungunya cases reported by EuroTravNet core sites
in 2008 and the overlapping area of habitation of Aedes albopictus.
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Latin America need to be sensitised to the epidemiology
of this disease [24].
Tuberculosis is of concern for European public health
authorities. In 2006, the EuroTB network reported
88,113 cases of TB in the EU. As reported here, high
numbers of cases are of complicated forms, including
MDR or XDR TB, and reported amongst vulnerable
populations, such as foreign-born VFRs and immigrants.
ECDC has published a Framework Action Plan to Fight
TB in the EU[25], which provides a roadmap to better
control and ultimately eliminate TB in the EU. Euro-
TravNet sites will continue to play an important role in
the surveillance of this disease.
The pre-travel consultation is an opportunity to
review a traveller’s vaccination history, including both
routine schedule vaccines and travel-specific vaccines. In
this study, a large number of potentially vaccine-preven-
table diseases were reported (166 cases). In the cases of
diphtheria, the mother had not received pre-travel
advice. During the 1990 s, the incidence of diphtheria
rose in the newly independent states of the former
Soviet Union, due in part to a failure of diphtheria con-
trol following the break-up of the Soviet Union. In East-
ern Europe (Russian Federation, Ukraine, and other
countries of the former Soviet Union, including Latvia)
the number of cases has declined since the outbreaks in
the 1990 s [26]. Cases of diphtheria may occur in unvac-
cinated travellers to endemic regions, especially VFRs.
Given the number of cases of Influenza-like illnesses
reported to EuroTravNet in 2008, and the experience
gained in the H1N1 pandemic, vaccination against influ-
enza should continue to be offered to all travellers at
risk of complications from this illness. Healthy indivi-
duals travelling to tropical and sub-tropical regions,
notably SSA, can also consider vaccination as influenza
has been shown to be one of the most frequently occur-
ring vaccine preventable diseases [27]. The issue of the
use of appropriate hemisphere influenza vaccine needs
to be highlighted as a travel health issue [28]. Travellers
should be reminded of the importance of hand hygiene
and avoid travel if they have a respiratory illness.
This report also confirms the increasing importance of
rickettsioses in ill returned travellers, particularly Afri-
can tick-bite fever that afflicts travellers to SSA [29]
who have often visited safari and game park areas. It
also highlights the potential rabid animal-related injury
[30], and the importance of including rabies prevention
advice and consideration of pre-exposure vaccination
during the pre-travel consultation[31]. Finally, the inci-
dence of tick-borne encephalitis (TBE), the most impor-
tant flavivirus infection of the central nervous system in
Europe and Russia [32], is increasing. The risk remains
relevant for unvaccinated travellers and illustrates the
need for pre-travel advice for travellers within Europe
[33].
Conclusions
As Europe is the worldwide continental leader in inter-
national tourism expenditure, the practice of travel med-
icine, and the framework for guidelines, is of increasing
importance. Our study provides a comprehensive analy-
sis of the epidemiology of travel related illness in Europe
and opens the door for prospective studies and surveil-
lance of specific diseases of concern within Europe.
Aside from gastro-intestinal diseases, febrile systemic ill-
nesses, dermatological conditions and respiratory ill-
nesses, the spectrum of disease in returned travellers is
complex. Certain travel destinations are associated with
a higher proportionate morbidity for certain diseases.
The country of origin of settled immigrants in Europe
has a major role to play in disease profiles; individuals
presenting with Chagas Disease to EuroTravNet core
sites are usually migrants from Bolivia and P. falciparum
malaria occurs predominantly in migrant families who
originate in sub-Saharan Africa and the Indian Ocean
Islands.
This study shows that travel within and outside Eur-
ope has many implications for health and such data are
key to prioritising pre-travel intervention strategies and
post-travel decision making.
The spectrum of travel associated morbidity shows
that there is a need to dispel the misconception that tra-
vel, close to home, in Europe, is without significant
health risk. Pre-travel health advice is also clearly indi-
cated for travel within Europe. In 2010, EuroTravNet,
commissioned by ECDC, will be working on “Travel
health country information for travel within EU/EFTA”,
in order to provide comprehensive guidance on travel
health risks within Europe for travellers and health
professionals.
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